Has Shannon Lamb, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,197 in general payments to Shannon Lamb, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shannon Lamb, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shannon Lamb, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shannon Lamb, MD

Urogynecology and Reconstructive Pelvic Surgery · Washington, DCNPI 1275506487

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,500 of the $7,197 with a category attached, or 76.4%. 7 manufacturers reported payments, led by Merck at 58.6% of the total. Reporting peaked in 2020 at $2,839 and has fallen 94.6% since, to $154 in 2025.

$7,197in general payments, 2019–2025

Across 16 payments — averaging $449.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$4K
Organon$1K
Applied Medical Resources Corporation$939
Axonics, Inc.$292
Coloplast$273
AbbVie$63
plus $41 from 1 others

What the payments were for

Speaking & faculty fees$5,50076%
Travel & lodging$84812%
Food & beverage$84912%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	4	$4,214
Organon	1	$1,375
Applied Medical Resources Corporation	2	$939
Axonics, Inc.	3	$292
Coloplast	2	$273
AbbVie	3	$63
Biotissue Holdings Inc.	1	$41

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$23,093

Medicare patients

Services billed

304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urogynecology and reconstructive pelvic surgery in Washington

Cheryl IglesiaWashington$9K
Andrew SokolWashington$9K
Charelle Carter-BrooksWashington$7K
Lee RichterWashington$7K
Abigail DavenportWashington$6K
Moiuri SiddiqueWashington$4K
Rachael SussmanWashington$3K
Alexis DieterWashington$3K
Helen ZhangWashington$3K
Tatiana SansesWashington$2K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →